- Home
- ADXN vs TOVX Comparison
ADXN vs TOVX Comparison
Compare ADXN & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADXN | TOVX |
|---|---|---|
| Founded | 2002 | 2001 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6M | 10.1M |
| IPO Year | 2019 | 2012 |
Fundamental Metrics
Financial Performance| Metric | ADXN | TOVX |
|---|---|---|
| Price | $3.70 | $0.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 122.1K | ★ 496.8K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $86.57 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.40 | $0.16 |
| 52 Week High | $12.05 | $0.86 |
Technical Indicators
Market Signals| Indicator | ADXN | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 33.97 | 55.94 |
| Support Level | N/A | $0.22 |
| Resistance Level | $7.37 | $0.26 |
| Average True Range (ATR) | 0.60 | 0.01 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 9.27 | 63.40 |
Price Performance
Historical ComparisonAbout ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.